Indeed, anti-inflammatory therapies including anti-IL1β inhibition and colchicine have been studied in randomized controlled trials (RCTs) in patients at risk for and with coronary artery disease (CAD) and have shown reductions in cardiovascular events [11–13]. This evidence concerns the gene IL1B and coronary artery disorder.